Form 8-K

8-K — Curanex Pharmaceuticals Inc

Accession: 0001493152-26-038764

Filed: 2026-08-17

Period: 2026-08-14

CIK: 0002025942

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Material Modifications to Rights of Security Holders

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

GRAPHIC (ex3-1_001.jpg)

GRAPHIC (ex3-1_002.jpg)

GRAPHIC (ex3-1_003.jpg)

GRAPHIC (ex3-1_004.jpg)

GRAPHIC (ex3-1_005.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0002025942

2026-08-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 14, 2026

Curanex

Pharmaceuticals Inc

(Exact

name of registrant as specified in its charter)

Nevada

001-42815

83-0741390

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

Jericho Plaza, Suite 101B

Jericho,

11753

(Address of principal executive

offices)

(Zip Code)

(718)

673-6078

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of exchange on which registered

Common Stock, par value

$0.0001 per share

CURX

The Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.03. Material

Modification to Rights of Security Holders.

The

information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

Item

5.03.

Amendments

to Articles of Incorporation or Bylaws; Change in Fiscal Year.

previously disclosed by Curanex Pharmaceuticals Inc (the “Company”), on May 31, 2026, the board of directors of the Company

(the “Board”) approved by unanimous written consent, and on June 11, 2026, holders of a majority of the outstanding voting

power of the Company, acting by written consent, in accordance with the applicable provisions of the Nevada Revised Statutes (“NRS”)

and the Company’s Amended and Restated Articles of Incorporation, as amended (the “Articles of Incorporation”),

and its Bylaws, approved a reverse stock split of the issued

and outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio

of not less than 1-for-10 and not more than 1-for-50 (the “Reverse Split Range”) and a form of a Certificate of Amendment

to the Articles of Incorporation (the “Certificate of Amendment”), and granted the Board the discretionary authority to determine

the exact ratio of a reverse stock split within the Reverse Split Range and to effect a reverse stock split at such time and date, if

at all, as to be determined by the Board in its sole discretion. On July 22, 2026, the Board approved, by unanimous written consent,

a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s Common

Stock.

August 14, 2026, the Company filed the Certificate of Amendment with the Nevada Secretary of State in accordance with NRS 78.390, to

become effective at 12:01 a.m. Pacific Time on August 20, 2026 (the “Effective Time”), implementing the Reverse Stock Split.

After the Effective Time, it is expected the Common Stock will begin trading on Nasdaq on a reverse split-adjusted basis when the market

opens on August 20, 2026, under the existing trading symbol “CURX” but having a new CUSIP number.

the Effective Time, every 20 shares of Common Stock issued and outstanding will be automatically converted into one (1) issued and outstanding

share of Common Stock, resulting in approximately 1,568,241 shares of Common Stock, subject to adjustments (based on 31,364,812 shares

of Common Stock outstanding immediately prior to the Effective Time). The total number of shares of Common Stock authorized for issuance,

475,000,000 shares, and the par value per share of the Common Stock, $0.0001 will remain unchanged.

addition, as a result of the effectiveness of the Reverse Stock Split, proportionate adjustments will be made to the number of shares

of Common Stock underlying the Company’s outstanding equity awards under the Company’s 2026 Equity Incentive Plan as well

as the exercise and grant prices of such equity awards, as applicable. The total number of shares of the Company’s

preferred stock, par value $0.0001 per share, authorized for issuance will remain at 25,000,000. Furthermore, no change will be made

to the number of issued and outstanding shares of the Company’s Series A Preferred Stock, par value $0.0001 per share.

fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive

fractional shares as a result of the Reverse Stock Split will be entitled to have such fractional share rounded up to the nearest whole

share and, as such, any stockholder who otherwise would have held a fractional share after giving effect to the Reverse Stock Split will

instead hold one whole share of Common Stock. No

cash or other consideration will be paid in connection with any fractional shares that would otherwise have resulted from the Reverse

Stock Split. VStock

Transfer, LLC, the Company’s transfer agent, is acting as the exchange agent for the Reverse Stock Split and will provide instructions

to stockholders of record regarding the process for exchanging shares.

The

purpose of effecting the Reverse Stock Split is to regain compliance with the $1.00 minimum bid price requirement set forth in Nasdaq

Listing Rule 5550(a)(2) for continued listing on Nasdaq.

The

foregoing description of the Certificate of Amendment is qualified in its entirety by reference to the form of Certificate of Amendment,

a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item

9.01. Financial Statements and Exhibits

(d)

Exhibits

Number

Description

3.1

Certificate of Amendment filed with the Secretary of State of Nevada

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

Curanex Pharmaceuticals Inc

Date: August 17, 2026

By:

/s/

Jun Liu

Name:

Jun Liu

Title:

Chief Executive Officer

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit 3.1

GRAPHIC

Filename: ex3-1_001.jpg · Sequence: 3

Binary file (212019 bytes)

Download ex3-1_001.jpg

GRAPHIC

Filename: ex3-1_002.jpg · Sequence: 4

Binary file (512044 bytes)

Download ex3-1_002.jpg

GRAPHIC

Filename: ex3-1_003.jpg · Sequence: 5

Binary file (424606 bytes)

Download ex3-1_003.jpg

GRAPHIC

Filename: ex3-1_004.jpg · Sequence: 6

Binary file (364867 bytes)

Download ex3-1_004.jpg

GRAPHIC

Filename: ex3-1_005.jpg · Sequence: 7

Binary file (313867 bytes)

Download ex3-1_005.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 12

v3.26.1

Cover

Aug. 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 14, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-42815

Entity Registrant Name

Curanex

Pharmaceuticals Inc

Entity Central Index Key

0002025942

Entity Tax Identification Number

83-0741390

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Jericho Plaza

Entity Address, Address Line Two

Suite 101B

Entity Address, City or Town

Jericho

Entity Address, State or Province

Entity Address, Postal Zip Code

11753

City Area Code

(718)

Local Phone Number

673-6078

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.0001 per share

Trading Symbol

CURX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration